Patents by Inventor Tsukasa Suzuki
Tsukasa Suzuki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092953Abstract: The present invention provides a novel copolymer available for a drug delivery technique. More particularly, a novel copolymer for a drug delivery carrier targeting a tumor is provided. The present invention relates to a copolymer comprising structural units represented by the following formulas (A), (B), and (C): wherein R1, R2, and R3 are the same or different and represent a hydrogen atom or a C1-3 alkyl group, R4 represents a C1-3 alkyl group, R5 represents a hydrogen atom, a C1-18 alkyl group, a 3- to 8-membered cycloalkyl group optionally having a substituent, an adamantyl group, a C6-18 aryl group optionally having a substituent, or a 5- to 10-membered heteroaryl group optionally having a substituent, X1, X2, and X3 are the same or different and represent an oxygen atom, a sulfur atom, or N—R7, R6 represents a hydrogen atom, a leaving group, or a linker, R7 represents a hydrogen atom or a C1-3 alkyl group, m represents an integer of 1 to 100, and n represents an integer of 0 to 3.Type: ApplicationFiled: February 7, 2022Publication date: March 21, 2024Applicant: KOWA COMPANY, LTD.Inventors: Ryo KANAYA, Kenichi SUZUKI, Tsukasa CHIDA, Nobuhiro FUJIMAKI, Marina ECHIGO, Seiji MIURA
-
Publication number: 20240059795Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: October 27, 2023Publication date: February 22, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20230212315Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: December 15, 2022Publication date: July 6, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20220267470Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor DC/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: April 26, 2022Publication date: August 25, 2022Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Patent number: 11242086Abstract: A vehicle steering device includes a turning shaft held in a housing so as to be movable in the axial direction, a ball screw transmitting drive force produced by an electric motor to the turning shaft, a bearing supporting a nut, which is a component of the ball screw, so as to be rotatable relative to the housing, and annular elastic members that support side faces of the bearing in the axial direction of the turning shaft across the entire circumference, and are formed of an elastic material. The elastic members include respective first elastic portions having a first load characteristic that gently increases the ratio of compression load per a unit compression amount deforming in the axial direction of the turning shaft, and respective second elastic portions having a second load characteristic that keenly increases the ratio in comparison with the first load characteristic.Type: GrantFiled: June 29, 2017Date of Patent: February 8, 2022Assignee: HITACHI ASTEMO, LTD.Inventors: Yukinari Sato, Takayuki Tetsuka, Shingo Ishige, Akira Shirakawa, Tsukasa Suzuki
-
Patent number: 11214623Abstract: The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for FVIII to be used for the method of measuring the reactivity of FVIII in the presence of a substance having an activity of functionally substituting for FVIII. As a result, the inventors discovered that by using the produced antibodies, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately by one-stage clotting assay based on APTT, and also that FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately by Bethesda assay based on APTT.Type: GrantFiled: September 24, 2015Date of Patent: January 4, 2022Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Atsushi Muto, Takehisa Kitazawa, Tsukasa Suzuki
-
Patent number: 11041572Abstract: An annular valve in which the shape of a sealing surface of a valve body is optimized thus suppressing the occurrence of pressure loss in gas on the periphery of the sealing surface and extending the service life of the annular valve.Type: GrantFiled: March 16, 2018Date of Patent: June 22, 2021Inventors: Masaru Fujinami, Hirofumi Himei, Tsukasa Suzuki, Kazuhiro Shimizu, Shuji Ishihara, Kazuki Takizawa, Kouichi Takemoto
-
Publication number: 20210061346Abstract: A vehicle steering device includes a turning shaft held in a housing so as to be movable in the axial direction, a ball screw transmitting drive force produced by an electric motor to the turning shaft, a bearing supporting a nut, which is a component of the ball screw, so as to be rotatable relative to the housing, and annular elastic members that support side faces of the bearing in the axial direction of the turning shaft across the entire circumference, and are formed of an elastic material. The elastic members include respective first elastic portions having a first load characteristic that gently increases the ratio of compression load per a unit compression amount deforming in the axial direction of the turning shaft, and respective second elastic portions having a second load characteristic that keenly increases the ratio in comparison with the first load characteristic.Type: ApplicationFiled: June 29, 2017Publication date: March 4, 2021Inventors: Yukinari Sato, Takayuki Tetsuka, Shingo Ishige, Akira Shirakawa, Tsukasa Suzuki
-
Publication number: 20200370668Abstract: An annular valve in which the shape of a sealing surface of a valve body is optimized thus suppressing the occurrence of pressure loss in gas on the periphery of the sealing surface and extending the service life of the annular valve.Type: ApplicationFiled: March 16, 2018Publication date: November 26, 2020Inventors: Masaru FUJINAMI, Hirofumi HIMEI, Tsukasa SUZUKI, Kazuhiro SHIMIZU, Shuji ISHIHARA, Kazuki TAKIZAWA, Kouichi TAKEMOTO
-
Patent number: 10450381Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: GrantFiled: April 19, 2016Date of Patent: October 22, 2019Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Patent number: 10451627Abstract: The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.Type: GrantFiled: June 25, 2014Date of Patent: October 22, 2019Assignees: CHUGAI SEIYAKU KABUSHIKI KAISHA, JSR CORPORATION, JSR LIFE SCIENCES CORPORATIONInventors: Toshihiko Ohtomo, Jun Amano, Hideki Adachi, Tsukasa Suzuki, Motoaki Mizuuchi, Tetsuji Yamaguchi, Seiki Wakui
-
Publication number: 20190315884Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: July 2, 2019Publication date: October 17, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20170275376Abstract: The present inventors attempted to produce antibodies that neutralize the activity of a substance having an activity of functionally substituting for FVIII to be used for the method of measuring the reactivity of FVIII in the presence of a substance having an activity of functionally substituting for FVIII. As a result, the inventors discovered that by using the produced antibodies, FVIII activity in the plasma of a hemophilia A patient can be evaluated accurately by one-stage clotting assay based on APTT, and also that FVIII inhibitor titer in the plasma of a hemophilia A patient carrying a FVIII inhibitor can be evaluated accurately by Bethesda assay based on APTT.Type: ApplicationFiled: September 24, 2015Publication date: September 28, 2017Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Atsushi Muto, Takehisa Kitazawa, Tsukasa Suzuki
-
Publication number: 20170022293Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: October 7, 2016Publication date: January 26, 2017Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Patent number: 9550835Abstract: As a result of producing anti-DDR1 antibodies and conducting extensive studies on the antitumor activity thereof, antibodies that bind to the stalk domain in the amino acid sequence of human DDR1 were found to have a potent activity even when used alone compared to antibodies that bind to other domains. It was also found that the antibodies have one or more activities selected from the group consisting of: (i) an activity to suppress cell proliferation, (ii) an activity to inhibit cell migration, (iii) an activity to inhibit phosphorylation of DDR1 in cells, (iv) an activity to be taken up into cells, (v) an activity to decrease the expression level of DDR1 in cells, and (vi) an activity to decrease the expression level of TGF-? in cells.Type: GrantFiled: August 23, 2012Date of Patent: January 24, 2017Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Mei Ono, Yuji Sano, Tsukasa Suzuki
-
Publication number: 20170010270Abstract: The present invention relates to a method for assaying soluble GPC3 protein in a test sample, comprising using two different antibodies binding to different epitopes present in the N-terminal region of GPC3 protein.Type: ApplicationFiled: June 25, 2014Publication date: January 12, 2017Applicants: CHUGAI SEIYAKU KABUSHIKI KAISHA, JSR CORPORATION, JSR LIFE SCIENCES CORPORATIONInventors: Toshihiko OHTOMO, Jun AMANO, Hideki ADACHI, Tsukasa SUZUKI, Motoaki MIZUUCHI, Tetsuji YAMAGUCHI, Seiki WAKUI
-
Publication number: 20160222129Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: ApplicationFiled: April 19, 2016Publication date: August 4, 2016Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Patent number: 9334331Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.Type: GrantFiled: November 17, 2011Date of Patent: May 10, 2016Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Zenjiro Sampei, Tetsuo Kojima, Tetsuhiro Soeda, Atsushi Muto, Takehisa Kitazawa, Yukiko Nishida, Chifumi Imai, Tsukasa Suzuki, Kazutaka Yoshihashi
-
Publication number: 20160053019Abstract: The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.Type: ApplicationFiled: September 9, 2015Publication date: February 25, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Takehisa Kitazawa, Tsukasa Suzuki, Shigehisa Nagahashi, Hajime Miyamoto
-
Patent number: 9175091Abstract: The present inventors have succeeded in producing anti-AXL antibodies with specific functions. The present inventors also discovered that the antibodies have an angiogenesis-suppressive effect and an antitumor effect, and thereby completed the present invention. The anti-AXL antibodies of the present invention are useful as angiogenesis inhibitors and agents for inducing or inhibiting phosphorylation activity.Type: GrantFiled: November 14, 2008Date of Patent: November 3, 2015Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Takehisa Kitazawa, Tsukasa Suzuki, Shigehisa Nagahashi, Hajime Miyamoto